The effect of short-term intensive insulin therapy in newly-diagnosed Type-2 diabetic patients

Abstract

Objectives: We aimed to determine the effect of short-term intensive insulin therapy (SIIT) on long-term glycemic control in newly-diagnosed Type-2 diabetes mellitus (nT2DM) patients.
 Methods: In this retrospectively study conducted at Sakarya University Medical Faculty Training and Research Hospital Outpatient Clinic between 2016 and 2019, 65 nT2DM patients were enrolled soon after their SIIT was initiated and were followed for at least a year. Intensive insulin treatment was discontinued after three or 12 months in a total of 65 (23–73-year-old) patients who had been newly diagnosed with T2DM. Intensive insulin therapy was discontinued when glycemic control and the target Glycated Hemoglobin (HbA1c) level had been attained, after which oral anti-diabetic drug (OAD), long-term insulin, and diet therapies were pursued.
 Results: There was a significant decrease in mean HbA1c from 11.25±1.96% to 6.67±1.07%. Fasting plasma glucose (FPG) was found to be an independent predictor of whether intensive insulin therapy could be discontinued after three months in a model that included FPG, HbA1c, and body mass index measured at baseline. Patients with FPG >13.8 mmol/L were 7.6 times more likely to require intensive insulin therapy beyond three months. There were significant decreases in HbA1c and low-density lipoprotein-cholesterol concentration, but no change in C-peptide between baseline and 3 months of therapy.
 Conclusion: These results demonstrate that in nT2DM patients, intensive insulin therapy could be effective on long-term glycemic control and high FPG prior to three months of SIIT may predict poor long-term glycemic control.
 doi: https://doi.org/10.12669/pjms.37.7.4013
 How to cite this:Karacaer C, Demirci T, Cengiz H, Varim C, Tamer A. The effect of short-term intensive insulin therapy in newly-diagnosed Type-2 diabetic patients. Pak J Med Sci. 2021;37(7):---------. doi: https://doi.org/10.12669/pjms.37.7.4013
 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oral antidiabetic therapy versus early insulinization on glycemic control in newly diagnosed type 2 diabetes patients: a retrospective matched cohort study

“…This led to a higher rates of well-controlled glycemic levels (78.8% vs. 67.3%), and a shorter timeframe (442.08 ± 350.06 vs. 513.92 ± 388.93 days) in OAD group compared to early insulinization group.Our study ndings differ from prior investigations conducted by Weng et al,Ryan et al, and Karacaer et al. (8,9,25), which showed a greater percentage of patients attaining target glycemic control within a shorter timeframe in the insulin group compared to those receiving OADs. Their methods involved continuous subcutaneous infusion insulin (CS II) or multiple daily insulin injections (MDI) with daily dosage adjustments (8, 9, 25), contrasting our insulin approach characterized by reduced intensity of injection and monitoring.…”

Effect of Gegen Qinlian Decoction combined with dietary management on patients with damp-heat Type-2 diabetes mellitus and metabolic syndrome

“… 2 , 3 Currently, measures such as insulin injections, oral hypoglycemic drugs, antiplatelet aggregation drugs, and blood lipid regulators are commonly used for managing patients with T2DM and MetS (T2DM MetS). 3 , 4 These measures can alleviate clinical symptoms to a certain extent, but the overall effect is suboptimal. 2 , 4 , 5 In addition to pharmacological agents, dietary management is also an important way of managing T2DM with MetS.…”

Efficacy of a basal insulin dose management smartphone application for controlling fasting blood glucose in patients with type‐2 diabetes mellitus: A single‐centre, randomised clinical study

“…[3][4][5] Reducing the hyperglycemic status of hospitalised patients can shorten the length of stay, improve prognosis and save hospitalisation costs. [6][7][8] In T2DM patients with poor glycaemic control, especially those with glycosylated haemoglobin (HbA1c) ≥ 8.0%, the absolute contribution of fasting hyperglycaemia to excess HbA1c value increases dramatically as blood glucose levels deteriorate. 9,10 Therefore, aggressive use of basal insulin (BI) to bring fasting glucose to target is particularly important for treating HH and improving the prognosis of patients with T2DM.…”

“…Basal–prandial insulin therapy (BPIT) is the preferred treatment for noncritically ill patients 3–5 . Reducing the hyperglycemic status of hospitalised patients can shorten the length of stay, improve prognosis and save hospitalisation costs 6–8 …”